Discovery of a Novel Hsp90 Inhibitor by Fragment Linking
暂无分享,去创建一个
Mark Whittaker | Thomas Hesterkamp | Oliver Barker | M. Varasi | T. Hesterkamp | J. Barker | M. Whittaker | O. Ichihara | John J Barker | Stephen M Courtney | Mihaly Gardiner | Osamu Ichihara | Owen Mather | Christian A G N Montalbetti | Annett Müller | Mario Varasi | Christopher J Yarnold | C. Yarnold | C. Montalbetti | S. Courtney | Oliver Barker | A. Müller | M. Gardiner | O. Mather | Christopher J. Yarnold | Annett Müller
[1] Christopher W. Murray,et al. Entropic Consequences of Linking Ligands , 2006 .
[2] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[3] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[4] M. Adler,et al. Potent Triazolothione Inhibitor of Heat‐Shock Protein‐90 , 2009, Chemical biology & drug design.
[5] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[6] Lisa M. Shewchuk,et al. Crystallization of protein–ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.
[7] Yves L Janin,et al. ATPase inhibitors of heat-shock protein 90, second season. , 2010, Drug discovery today.
[8] Mark Whittaker,et al. Fragment-based activity space: smaller is better. , 2008, Current opinion in chemical biology.
[9] P. Hajduk,et al. SAR by NMR: An Analysis of Potency Gains Realized Through Fragment‐linking and Fragment‐elaboration Strategies for Lead Generation , 2006 .
[10] T. Hesterkamp,et al. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. , 2007, Current topics in medicinal chemistry.
[11] F. Petitet,et al. Assessing the chemical diversity of an hsp90 database. , 2010, European journal of medicinal chemistry.
[12] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[13] Gianni Chessari,et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.
[14] Laura G. Dubois,et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. , 2009, Journal of medicinal chemistry.
[15] K. Kitaura,et al. Fragment molecular orbital method: an approximate computational method for large molecules , 1999 .
[16] W. Jencks,et al. On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[17] Alexander A Alex,et al. Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.
[18] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[19] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[20] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[21] Mark Whittaker,et al. The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..
[22] T Neumann,et al. SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.
[23] Kazuo Kitaura,et al. Extending the power of quantum chemistry to large systems with the fragment molecular orbital method. , 2007, The journal of physical chemistry. A.
[24] Edward R Zartler,et al. Practical aspects of NMR-based fragment discovery. , 2007, Current topics in medicinal chemistry.
[25] K. Bhalla,et al. Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.
[26] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[27] Mark Whittaker,et al. Fragment‐based Identification of Hsp90 Inhibitors , 2009, ChemMedChem.